PharmaNutra Targets GLP-1 Muscle Loss Risk With New Myosave® Study

PharmaNutra SpA (IT:PHN) announced an update on their ongoing clinical study.

The study “Evaluating the Effect of a Food for Special Medical Purposes Containing Essential Amino Acids (EAA), Carnitine, Arginine, and Sucrosomial Minerals on the Preservation of Appendicular Skeletal Muscle Mass (ASMM) During a Weight Loss Program With GLP-1 Receptor Agonists” aims to see if a targeted nutrition product can protect muscle while patients lose weight on GLP-1 drugs. This is important because preserving muscle may improve long term health outcomes and could support wider, safer use of GLP-1 therapies in obesity care.

The main treatment tested is Myosave®, a Food for Special Medical Purposes designed to support muscle health during weight loss. It combines key amino acids and minerals and is compared with a placebo product that looks and is taken the same way.

This is an interventional, randomized study where participants are split into two parallel groups. It is quadruple blind, so patients, doctors, study staff, and outcome assessors do not know who takes Myosave® or placebo, and the main goal is supportive care rather than testing a drug to cure a disease.

Participants take Myosave® or placebo twice a day for 24 weeks while continuing their usual GLP-1 or dual GIP/GLP-1 therapy. The key outcome is how well muscle mass is preserved during this period, measured with non invasive tools and compared between the two groups.

The trial is currently listed as recruiting, meaning enrollment is underway but no results are available yet. Muscle protection data will likely be important for doctors who worry about lean mass loss with rapid GLP-1 driven weight reduction.

Key timing markers include the initial submission on 2025-12-29, which signals when the trial plan entered the formal registry. The latest update on 2026-03-20 confirms the protocol and status have been recently reviewed and suggests active operational progress.

The primary completion date will mark when main muscle mass data are collected, which is the next major catalyst for investors. The estimated final completion date will follow later, after all follow up and analysis are done, setting the horizon for any peer reviewed publications or label related discussions for Myosave®.

For PharmaNutra S.p.A. (PHN), a positive outcome could strengthen its positioning in the fast growing GLP-1 ecosystem, not by competing with drug makers but by offering an add on nutritional solution. This might support a re rating of the stock over time if investors see recurring demand tied to the expanding base of GLP-1 users.

The study also feeds into a wider trend where investors look for “picks and shovels” around GLP-1, from diagnostics to supportive care products. Success here could draw greater attention to smaller nutrition players and may trigger competitive responses from larger consumer health and supplement companies.

In the near term, the update mainly signals execution rather than a clear earnings impact, so share price reaction may stay muted until data arrive. Still, it adds to PHN’s clinical credibility and may support sentiment among long term holders who value evidence based differentiation over pure branding.

The trial is ongoing and the record has been recently updated, with further operational and design details available on the ClinicalTrials portal.

To learn more about IT:PHN’s potential, visit the PharmaNutra SpA drug pipeline page.